Healthcare products
Child Health
Deficiency States and Supplementation
Dermatological Health
Pain treatment
Gastrointestinal Health
Genitourinary Health
Cardiorespiratory Health
Corticotherapy
Oral-Pharyngeal Health
Fluid Therapy
CNS Treatment
Ernamín at the 55th Congress of the Spanish Society of Nephrology
Ernamín at the 55th Congress of the Spanish Society of Nephrology
From October 16–18, the 55th edition of the Congress of the Spanish Society of Nephrology (SEN) took place in Oviedo. For the first time, and following the launch of Ernamín, ERN Laboratories participated as a collaborator in the event, with a stand in the commercial exhibition area and by organizing a technical forum featuring high-level speakers.
The forum, titled “Use of Ketoanalogues for the Management of CKD in Spain: A New Reality”, brought together over one hundred nephrology professionals. Dr. Juan-Jesús Carrero, researcher at the Karolinska Institute in Sweden, and Dr. Pablo Molina, Head of the Nephrology Department at Hospital La Fe (València), presented evidence on low-protein diets in advanced CKD, the use of amino acid ketoanalogues in these patients, and the results of the ADHERENCE study. The forum was moderated by Dr. Huarte, Head of the Nephrology Department at Hospital San Millán-San Pedro de Logroño (La Rioja).
The ADHERENCE study is the first randomized clinical trial conducted with ketoanalogues in Spain, and its results, which reinforce existing evidence on the benefits of ketoanalogues, will be published soon in the journal Nefrología.
Ernamín is the only product available on the Spanish market (since last June) that contains a combination of essential amino acids and ketoanalogues, making it a unique nutritional tool for the dietary management of advanced CKD. Together with a very low-protein diet, Ernamín helps preserve kidney function, improves nutritional status, and delays the need for dialysis.
noticias relacionadas
Laboratorios ERN joins the Fundación Empresa y Clima (FEC) as a Silver member
We are proud to announce that Laboratorios ERN has officially joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing our commitment to climate action and global sustainability. This alliance allows us to become part of a business community committed to the transition toward a low-carbon economy, alongside other companies that share the […]
ERN Laboratories supports research into pediatric rare diseases at Sant Joan de Déu Hospital in Barcelona.
During 2026, ERN Laboratories will allocate €1 for each unit sold of Astenolit Infantil, a nutritional supplement designed to support children’s energy levels and immune defenses, to benefit pediatric rare disease research at Sant Joan de Déu. This initiative is part of ERN Laboratories’ longstanding commitment to pediatrics and child health, supporting projects that contribute […]
Ernamín at the 55th Congress of the Spanish Society of Nephrology
From October 16–18, the 55th edition of the Congress of the Spanish Society of Nephrology (SEN) took place in Oviedo. For the first time, and following the launch of Ernamín, ERN Laboratories participated as a collaborator in the event, with a stand in the commercial exhibition area and by organizing a technical forum featuring high-level […]
Incremental Drug Innovation: A Priority Focus for Laboratorios ERN
David Solanes López, General Manager of Laboratorios ERN, was appointed Academician of the Royal Academy of Pharmacy of Catalonia on October 6, 2025, in the industrial section. Solanes dedicated his induction speech to incremental innovation, an area closely linked to his professional career and to Laboratorios ERN’s commitment to developing solutions that improve patients’ lives. […]
FDA has approved intravenous fosfomycin for the treatment of cUTI
On October 22, 2025, the U.S. Food and Drug Administration (FDA) approved intravenous fosfomycin for the treatment of complicated urinary tract infections (cUTI). Laboratorios ERN expresses its satisfaction with the recent approval by the U.S. Food and Drug Administration (FDA) of intravenous fosfomycin for the treatment of patients aged 18 years and older with complicated […]